These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 24458223)

  • 1. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.
    Laserna E; Sibila O; Fernandez JF; Maselli DJ; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Chest; 2014 May; 145(5):1114-1120. PubMed ID: 24458223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant Pseudomonas aeruginosa.
    Cillóniz C; Gabarrús A; Ferrer M; Puig de la Bellacasa J; Rinaudo M; Mensa J; Niederman MS; Torres A
    Chest; 2016 Aug; 150(2):415-25. PubMed ID: 27060725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia.
    Sibila O; Laserna E; Maselli DJ; Fernandez JF; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Respirology; 2015 May; 20(4):660-6. PubMed ID: 25776134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
    Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
    Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of macrolide in treating adult hospitalized community-acquired pneumonia.
    Loh LC; Quah SY; Khoo SK; Vijayasingham P; Thayaparan T
    Respirology; 2005 Jun; 10(3):371-7. PubMed ID: 15955152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Empiric Antibiotic Treatment Regimens for Hospitalized, Non-severe Community-acquired Pneumonia: A Retrospective, Multicenter Cohort Study.
    Reeves SD; Hartmann AP; Tedder AC; Juang PA; Hofer M; Kollef MH; Micek ST; Betthauser KD
    Clin Ther; 2024 Apr; 46(4):338-344. PubMed ID: 38403509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The order of administration of macrolides and beta-lactams may impact the outcomes of hospitalized patients with community-acquired pneumonia: results from the community-acquired pneumonia organization.
    Peyrani P; Wiemken TL; Metersky ML; Arnold FW; Mattingly WA; Feldman C; Cavallazzi R; Fernandez-Botran R; Bordon J; Ramirez JA
    Infect Dis (Lond); 2018 Jan; 50(1):13-20. PubMed ID: 28699429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Asadi L; Sligl WI; Eurich DT; Colmers IN; Tjosvold L; Marrie TJ; Majumdar SR
    Clin Infect Dis; 2012 Aug; 55(3):371-80. PubMed ID: 22511553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic treatment outcomes in community-acquired pneumonia.
    Çilli A; Sayıner A; Çelenk B; Şakar Coşkun A; Kılınç O; Hazar A; Aktaş Samur A; Taşbakan S; Waterer GW; Havlucu Y; Kılıç Ö; Tokgöz F; Bilge U
    Turk J Med Sci; 2018 Aug; 48(4):730-736. PubMed ID: 30119147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
    Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
    Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
    Gilbert TT; Arfstrom RJ; Mihalovic SW; Dababneh AS; Varatharaj Palraj BR; Dierkhising RA; Mara KC; Lessard SR
    Am J Ther; 2020; 27(2):e177-e182. PubMed ID: 30418221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of macrolide treatment on long-term mortality in patients admitted to the ICU due to CAP: a targeted maximum likelihood estimation and survival analysis.
    Reyes LF; Garcia E; Ibáñez-Prada ED; Serrano-Mayorga CC; Fuentes YV; Rodríguez A; Moreno G; Bastidas A; Gómez J; Gonzalez A; Frei CR; Celi LA; Martin-Loeches I; Waterer G
    Crit Care; 2023 May; 27(1):212. PubMed ID: 37259125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia.
    Falcone M; Russo A; Shindo Y; Farcomeni A; Pieralli F; Cangemi R; Liu J; Xia J; Okumura J; Sano M; Jones C; Vannucchi V; Mancone M; Micek S; Xu F; Violi F; Kollef M
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Macrolide Deescalation in Severe Community-acquired Pneumonia.
    Hopkins TM; Juang P; Weaver K; Kollef MH; Betthauser KD
    Clin Ther; 2019 Dec; 41(12):2540-2548. PubMed ID: 31676040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrolides and mortality in critically ill patients with community-acquired pneumonia: a systematic review and meta-analysis.
    Sligl WI; Asadi L; Eurich DT; Tjosvold L; Marrie TJ; Majumdar SR
    Crit Care Med; 2014 Feb; 42(2):420-32. PubMed ID: 24158175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Combined β-Lactam/Macrolide Therapy on Mortality According to the Microbial Etiology and Inflammatory Status of Patients With Community-Acquired Pneumonia.
    Ceccato A; Cilloniz C; Martin-Loeches I; Ranzani OT; Gabarrus A; Bueno L; Garcia-Vidal C; Ferrer M; Niederman MS; Torres A
    Chest; 2019 Apr; 155(4):795-804. PubMed ID: 30471269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Community-acquired pneumonia due to gram-negative bacteria and pseudomonas aeruginosa: incidence, risk, and prognosis.
    Arancibia F; Bauer TT; Ewig S; Mensa J; Gonzalez J; Niederman MS; Torres A
    Arch Intern Med; 2002 Sep; 162(16):1849-58. PubMed ID: 12196083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of empiric β-lactam monotherapy and β-lactam-macrolide combination therapy in children hospitalized with community-acquired pneumonia.
    Ambroggio L; Taylor JA; Tabb LP; Newschaffer CJ; Evans AA; Shah SS
    J Pediatr; 2012 Dec; 161(6):1097-103. PubMed ID: 22901738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
    Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
    J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.